Navigation auf uzh.ch

Suche

UZH Innovation Hub

UZH spin-off Anaveon successfully closed a CHF 35 million Series A financing

UZH spin-off Anaveon successfully closed a CHF 35 million Series A financing with the lead investor Syncona Ltd. based in the a UK. Anaveon works on a new approach for developing immunotherapies for cancer. The technology was developed by Prof. Onur Boyman. The co-founder of Anaveon is Andreas Katopodis, a former director at Novartis Institutes of Biomedical Research. The company was created in December 2017 and received its seed financing from the UZH Life Sciences Fund.

UZH Innovation Hub

Weiterführende Informationen